Accessibility Menu
Arrow-Thin-Down
S&P 500
6,699.40
-0.5%
-35.95
Arrow-Thin-Down
DJI
46,590.41
-0.7%
-334.33
Arrow-Thin-Down
NASDAQ
22,740.40
-0.9%
-213.27
Arrow-Thin-Down
Bitcoin
$109,293
+1.0%
+$1,041.67
Arrow-Thin-Down
AAPL
$258.4
-1.7%
-$4.37
Arrow-Thin-Down
AMZN
$217.95
-1.8%
-$4.08
Arrow-Thin-Down
GOOG
$252.53
+0.5%
+$1.19
Arrow-Thin-Down
META
$733.41
+0.0%
+$0.14
Arrow-Thin-Down
MSFT
$520.54
+0.6%
+$2.88
Arrow-Thin-Down
NVDA
$180.05
-0.6%
-$1.12
Arrow-Thin-Down
TSLA
$438.89
-0.8%
-$3.72
Daily Stock GainersDaily Stock LosersMost Active Stocks
Athira Pharma Stock Quote

Athira Pharma (NASDAQ: ATHA)

$3.93
(-7.7%)
-0.33
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.93
Daily Change
(-7.7%) $0.33
Day's Range
$3.85 - $4.2
Previous Close
$3.93
Open
$4.2
Beta
1.38
Volume
35,340
Average Volume
28,507
Sector
Health Care
Market Cap
15.5M
Market Cap / Employee
$3.93M
52wk Range
$2.2 - $8.26
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$15.44
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Athira Pharma Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ATHA-25.71%-97.97%-54.12%-98%
S&P+14.5%+93.32%+14.09%+102%

Athira Pharma Company Info

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

News & Analysis

Featured Article

Athira (ATHA) Q2 Loss Narrows 74%

Motley Fool Markets Team  |  Aug 7, 2025
Featured Article

Why Athira Pharma Stock Imploded Today

Its mid-stage clinical trial failed to help patients with Alzheimer's.

Alex Carchidi  |  Jun 22, 2022

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.20M17.4%
Market Cap$11.91M-88.3%
Market Cap / Employee$0.46M0.0%
Employees26-61.2%
Net Income-$6.97M74.1%
EBITDA-$7.09M74.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$19.89M-75.8%
Accounts Receivable$0.00M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.58M-43.1%
Short Term Debt$0.44M12.3%

Ratios

Q2 2025YOY Change
Return On Assets-81.54%-10.5%
Return On Invested Capital-73.32%-134.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$7.00M68.7%
Operating Free Cash Flow-$7.00M68.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.300.510.300.37-60.86%
Price to Tangible Book Value2.063.942.483.16-66.81%
Enterprise Value to EBITDA2.331.782.632.40-2342.02%
Return on Equity-102.9%-110.8%-110.7%-103.8%22.75%
Total Debt$1.31M$1.22M$1.12M$1.02M-27.72%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services